« Return to News | Drug Sponsors

Shanghai Pharmaceuticals inks $3 billion in overseas contracts

Thursday, April 14, 2011 01:07 PM

Shanghai Pharmaceuticals will ink more than $3.06 billion worth of procurement contracts with 69 worldwide pharmaceutical companies this year, according to Global Times.

Pfizer, Sanofi-Aventis, Merck and Novo Nordisk are just a few involved, and the contracts are estimated to account for approximately 60% of Shanghai Pharmaceuticals' total procurement of drugs and medical devices.

Li Yongzhong, vice president of Shanghai Pharmaceuticals, said that the company hopes to double its volume of business with overseas pharmaceutical companies in the future.

"Our value-added support is a big help for those overseas drug makers who can greatly benefit from the growing Chinese market," an officer surnamed Lu from the office of the board of directors of Shanghai Pharmaceuticals told the Global Times. "With our domestic resources, we can provide market entry support for new medicines, winning government tenders, relevant policy information, new product registration, and all other related fields."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.